Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 pricing pressures are capping revenue and profitability. The TrumpRx platform ...
Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...
Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease (AD). But perhaps the larger story associated with the unsurprising result is the market ...
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...
Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...
Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...
NEW YORK/LONDON, Nov 6 (Reuters) - The Pfizer (PFE.N), opens new tab and Novo Nordisk (NOVOb.CO), opens new tab battle for obesity drug developer Metsera (MTSR.O), opens new tab intensified on ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Ed Silverman, a senior ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Matthew Herper covers ...
Novo Nordisk A/S found a new leader for its investor relations department in an equity analyst who has recommended buying shares in the drugmaker for almost 15 years. Michael Novod, one the best known ...
London's Financial Times highlights improved weight loss from taking more Ozempic. Eli Lilly's Mounjaro still seems more effective. Novo Nordisk stock is responding positively to the news, up 2.1% ...
One day after announcing plans to cut 9,000 jobs in a major restructuring, Novo Nordisk has told its employees that office work will be mandatory at the start of next year. There is some flexibility ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results